Rosai-Dorfman Disease
Symptoms, Doctors, Treatments, Advances & More

Rosai-Dorfman Disease Overview

Save information for later
Sign Up

Learn About Rosai-Dorfman Disease

What is the definition of Rosai-Dorfman Disease?
Rosai-Dorfman disease is a benign disease which is characterized by over-production and accumulation of a specific type of white blood cell (histiocyte) in the lymph nodes of the body, most often those of the neck (cervical). Other lymph node groups may also be involved and, in some cases, abnormal accumulation of histiocytes may occur in other areas of the body (extranodal). The cause of this condition remains unknown, although altered immune responses and infectious agents may play a role.
What are the alternative names for Rosai-Dorfman Disease?
  • Rosai-Dorfman disease
  • RDD
  • Rosaï-Dorfman disease
  • SHML
  • Sinus histiocytosis with massive lymphadenopathy
Who are the top Rosai-Dorfman Disease Local Doctors?
Elite in Rosai-Dorfman Disease
Dr. Jason Young
Radiology
Elite in Rosai-Dorfman Disease
Dr. Jason Young
Radiology
Referral may be required

Mayo Clinic Hospital In Florida

4500 San Pablo Rd S, 
Jacksonville, FL 
904-953-2000
Languages Spoken:
English

Jason Young is a Radiologist practicing medicine in Jacksonville, Florida. Dr. Young is rated as an Elite provider by MediFind in the treatment of Rosai-Dorfman Disease. He is also highly rated in 3 other conditions, according to our data. His clinical expertise encompasses Rosai-Dorfman Disease, Erdheim-Chester Disease, Interstitial Lung Disease, and Primary Lymphoma of the Brain.

Elite in Rosai-Dorfman Disease
Elite in Rosai-Dorfman Disease
Referral may be required

MN - Cancer Hematology

200 1st St SW, 
Rochester, MN 
507-229-0068
Languages Spoken:
English
See accepted insurances

Jithma Abeykoon is a Hematologist practicing medicine in Rochester, Minnesota. Dr. Abeykoon is rated as an Elite provider by MediFind in the treatment of Rosai-Dorfman Disease. He is also highly rated in 14 other conditions, according to our data. His clinical expertise encompasses Waldenstrom Macroglobulinemia, Reticulohistiocytoma, Histiocytosis, Tissue Biopsy, and Bone Marrow Transplant.

 
 
 
 
Learn about our expert tiers
Learn More
Advanced in Rosai-Dorfman Disease
Dr. Tamara L. Musgrave
Hematology | Oncology
Advanced in Rosai-Dorfman Disease
Dr. Tamara L. Musgrave
Hematology | Oncology
Referral may be required

Ballad Health Cancer Care

743 Island Road, 
Bristol, VA 
423-844-1121
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tamara Musgrave is a Hematologist and an Oncologist practicing medicine in Bristol, Virginia. Dr. Musgrave is rated as an Advanced provider by MediFind in the treatment of Rosai-Dorfman Disease. She is also highly rated in 50 other conditions, according to our data. Her clinical expertise encompasses Paget Disease of the Breast, Thrombocytopenia, Neuroendocrine Tumor, and Angiosarcoma. Dr. Musgrave is board certified in American Board Of Internal Medicine.

View All Doctors
What are the latest Rosai-Dorfman Disease Clinical Trials?
Histiocytic Disorder Follow-up Study
Histiocytic Disorder Follow-up Study
Enrollment Status: Recruiting
Publish Date: June 12, 2026

Summary: The purpose of the study is to describe the burden of chronic health conditions, psychological dysfunction, chronic pain, healthcare utilization, worse health-related quality of life, overall mortality, and cause-specific mortality among individuals with histiocytic disorders

Match to trials
Find the right clinical trials for you in under a minute
Get started
In-human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
In-human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET
Who is this study for: Patients with Non-Hodgkin Lymphoma, Multiple Myeloma
Enrollment Status: Recruiting
Publish Date: February 05, 2026
Intervention Type: Drug
Study Drug: [68Ga]-Pentixafor
Study Phase: Early Phase 1

Summary: The purpose of this study is to determine the uptake of the imaging agent \[68Ga\]-pentixafor with PET/CT scans in people with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), and non-Hodgkin lymphoma (NHL), or you have histiocytic neoplasms (Langerhans cell histiocytosis (LCH), Erdheim-Chester disease (ECD) and/or Rosai-Dorfman disease (RDD).

View All Clinical Trials
Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center